Yariswamy Manjunath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yariswamy Manjunath has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Guangfu Li
Department of Surgery, University of Missouri, Columbia, Missouri, USA
51 shared publications - Jonathan B. Mitchem
MU Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA
51 shared publications - Jussuf T. Kaifi
University of Missouri
51 shared publications - Wesley C. Warren
Bond Life Sciences Center, University of Missouri, Columbia, USA
51 shared publications - Chi-Ren Shyu
University of Missouri
50 shared publications - Kanve Nagaraj Suvilesh
University of Missouri
50 shared publications
Latest Publications
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S3. Differentially expressed genes between Resistant and Sensitive PDTOs.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S3. Differentially expressed genes between Resistant and Sensitive PDTOs.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S9. Dose titration of epalrestat against PDTOs to determine the cytotoxicity.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S9. Dose titration of epalrestat against PDTOs to determine the cytotoxicity.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S3. Gene expression comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by whole transcriptome analysis.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S3. Gene expression comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by whole transcriptome analysis.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S12. Validation of AKR1B10 expression in an internal cohort of sensitive (n = 7) and resistance (n = 7) patient tumors to platinum-based doublet therapy.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S12. Validation of AKR1B10 expression in an internal cohort of sensitive (n = 7) and resistance (n = 7) patient tumors to platinum-based doublet therapy.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S4. Differentially expressed genes between resistant versus sensitive patient tumors (categorized based on PDTOs therapy outcome).
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S4. Differentially expressed genes between resistant versus sensitive patient tumors (categorized based on PDTOs therapy outcome).
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S13. Dose titration of commonly used cytotoxic agents against LUAC (n = 6) and LUSC (n = 6) cell lines.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S13. Dose titration of commonly used cytotoxic agents against LUAC (n = 6) and LUSC (n = 6) cell lines.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S14. Dose titration of commonly used cytotoxic agents against AKR1B10 knocked down and scramble shRNA treated A549 cells.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S14. Dose titration of commonly used cytotoxic agents against AKR1B10 knocked down and scramble shRNA treated A549 cells.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Purpose:Systemic treatments given to patients with non–small cell lung cancer (NSCLC) are often ineffective due to drug resistance. In the present study, we investigated patient-derived tumor organoids (PDTO) and matched tumor tissues from surgically treated patients with NSCLC to identify drug repurposing targets to overcome resistance toward standard-of-care platinum-based doublet chemotherapy.Experimental Design:PDTOs were established from 10 prospectively enrolled patients with non-metastatic NSCLC from resected tumors. PDTOs were compared with matched tumor tissues by histopathology/immunohistochemistry, whole exome sequencing, and transcriptome sequencing. PDTO growths and drug responses were determined by measuring 3D tumoroid volumes, cell viability, and proliferation/apoptosis. Differential gene expression analysis identified drug-repurposing targets. Validations were performed with internal/external data sets of patients with NSCLC. NSCLC cell lines were used for aldo-keto reductase 1B10 (AKR1B10) knockdown studies and xenograft models to determine the intratumoral bioavailability of epalrestat.Results:PDTOs retained histomorphology and pathological biomarker expression, mutational/transcriptomic signatures, and cellular heterogeneity of the matched tumor tissues. Five (50%) PDTOs were chemoresistant toward carboplatin/paclitaxel. Chemoresistant PDTOs and matched tumor tissues demonstrated overexpression of AKR1B10. Epalrestat, an orally available AKR1B10 inhibitor in clinical use for diabetic polyneuropathy, was repurposed to overcome chemoresistance of PDTOs. In vivo efficacy of epalrestat to overcome drug resistance corresponded to intratumoral epalrestat levels.Conclusions:PDTOs are efficient preclinical models recapitulating the tumor characteristics and are suitable for drug testing. AKR1B10 can be targeted by repurposing epalrestat to overcome chemoresistance in NSCLC. Epalrestat has the potential to advance to clinical trials in patients with drug-resistant NSCLC due to favorable toxicity, pharmacological profile, and bioavailability.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Purpose:Systemic treatments given to patients with non–small cell lung cancer (NSCLC) are often ineffective due to drug resistance. In the present study, we investigated patient-derived tumor organoids (PDTO) and matched tumor tissues from surgically treated patients with NSCLC to identify drug repurposing targets to overcome resistance toward standard-of-care platinum-based doublet chemotherapy.Experimental Design:PDTOs were established from 10 prospectively enrolled patients with non-metastatic NSCLC from resected tumors. PDTOs were compared with matched tumor tissues by histopathology/immunohistochemistry, whole exome sequencing, and transcriptome sequencing. PDTO growths and drug responses were determined by measuring 3D tumoroid volumes, cell viability, and proliferation/apoptosis. Differential gene expression analysis identified drug-repurposing targets. Validations were performed with internal/external data sets of patients with NSCLC. NSCLC cell lines were used for aldo-keto reductase 1B10 (AKR1B10) knockdown studies and xenograft models to determine the intratumoral bioavailability of epalrestat.Results:PDTOs retained histomorphology and pathological biomarker expression, mutational/transcriptomic signatures, and cellular heterogeneity of the matched tumor tissues. Five (50%) PDTOs were chemoresistant toward carboplatin/paclitaxel. Chemoresistant PDTOs and matched tumor tissues demonstrated overexpression of AKR1B10. Epalrestat, an orally available AKR1B10 inhibitor in clinical use for diabetic polyneuropathy, was repurposed to overcome chemoresistance of PDTOs. In vivo efficacy of epalrestat to overcome drug resistance corresponded to intratumoral epalrestat levels.Conclusions:PDTOs are efficient preclinical models recapitulating the tumor characteristics and are suitable for drug testing. AKR1B10 can be targeted by repurposing epalrestat to overcome chemoresistance in NSCLC. Epalrestat has the potential to advance to clinical trials in patients with drug-resistant NSCLC due to favorable toxicity, pharmacological profile, and bioavailability.